BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 21302643)

  • 1. Recent studies show promise for treating rare pancreatic tumors.
    Peres J
    J Natl Cancer Inst; 2011 Apr; 103(8):624-7. PubMed ID: 21474831
    [No Abstract]   [Full Text] [Related]  

  • 2. [More attention should be paid to the understanding of gastroenteropancreatic neuroendocrine tumors].
    Xu JM
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):158-60. PubMed ID: 22780939
    [No Abstract]   [Full Text] [Related]  

  • 3. Perspectives in the development of novel treatment approaches.
    Yao JC; Catena L; Colao A; Paganelli G
    Tumori; 2010; 96(5):858-73. PubMed ID: 21302643
    [No Abstract]   [Full Text] [Related]  

  • 4. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
    Raj N; Reidy-Lagunes D
    Pancreas; 2014 Nov; 43(8):1185-9. PubMed ID: 25333401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
    Boussaha T; Rougier P; Taieb J; Lepere C
    Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in the treatment of neuroendocrine tumors.
    Chan JA; Kulke MH
    Curr Oncol Rep; 2009 May; 11(3):193-9. PubMed ID: 19336011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
    Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
    von Mehren M
    Clin Colorectal Cancer; 2006 Nov; 6 Suppl 1():S30-4. PubMed ID: 17419150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
    Bousquet C; Lasfargues C; Chalabi M; Billah SM; Susini C; Vezzosi D; Caron P; Pyronnet S
    J Clin Endocrinol Metab; 2012 Mar; 97(3):727-37. PubMed ID: 22170729
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.